Rosopatamab
- Product Name
- Rosopatamab
- CAS No.
- 2260767-49-3
- Chemical Name
- Rosopatamab
- Synonyms
- Rosopatamab;Rosopatamab (anti-PSMA);Research Grade Rosopatamab;Research Grade Rosopatamab(DHG01304)
- CBNumber
- CB910616962
- Formula Weight
- 0
- MOL File
- Mol file
Rosopatamab Property
- form
- Liquid
- color
- Colorless to light yellow
Rosopatamab Chemical Properties,Usage,Production
Uses
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency[1].
in vivo
Combination of 177Lu-DOTA-rosopatamab (6 MBq, i.v., single) and Peposertib (HY-101570) achieves a 3 of 4 complete response rate in a LNCaP prostate cancer mice model[2].
177Lu-rosopatamab (anti-PSMA) (6 MBq, i.v., single) plus Peposertib (HY-101570) has 75% complete response (3/4) vs 25% complete response (1/4) in the 177Lu-anti-PSMA (6MBq) alone arm in the prostate BALB/c nude mice model[3].
IC 50
RDC Antibody
References
[1] Antonini P, et al. 177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT)[J]. 2022.
[2] Johnstone CN, et al. DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma. J Nucl Med. 2025 Jan 30:jnumed.124.268695. DOI:10.2967/jnumed.124.268695
[3] Johnstone C, et al. Addition of DNA dependent protein kinase (DNA-PK) inhibitor peposertib enhances efficacy of 177Lu-based radioimmunotherapy in pre-clinical models of prostate and renal cell carcinoma. 2023.
Rosopatamab Preparation Products And Raw materials
Raw materials
Preparation Products
Rosopatamab Suppliers
- Tel
- +1-781-999-5354;
- support@targetmol.com
- Country
- United States
- ProdList
- 39035
- Advantage
- 58